PL3681470T3 - Lactobacillus casei lub lactobacillus paracasei do stosowania w leczeniu infekcji clostridium difficile - Google Patents

Lactobacillus casei lub lactobacillus paracasei do stosowania w leczeniu infekcji clostridium difficile

Info

Publication number
PL3681470T3
PL3681470T3 PL18773856.2T PL18773856T PL3681470T3 PL 3681470 T3 PL3681470 T3 PL 3681470T3 PL 18773856 T PL18773856 T PL 18773856T PL 3681470 T3 PL3681470 T3 PL 3681470T3
Authority
PL
Poland
Prior art keywords
lactobacillus
treatment
clostridium difficile
difficile infections
paracasei
Prior art date
Application number
PL18773856.2T
Other languages
English (en)
Inventor
Andrea BIFFI
Original Assignee
Lac2biome S.r.l.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lac2biome S.r.l. filed Critical Lac2biome S.r.l.
Publication of PL3681470T3 publication Critical patent/PL3681470T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Dairy Products (AREA)
  • Medicinal Preparation (AREA)
PL18773856.2T 2017-09-12 2018-09-12 Lactobacillus casei lub lactobacillus paracasei do stosowania w leczeniu infekcji clostridium difficile PL3681470T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000101704A IT201700101704A1 (it) 2017-09-12 2017-09-12 Nuovo uso per trattamento delle infezioni da clostridium difficile
PCT/IB2018/056956 WO2019053604A1 (en) 2017-09-12 2018-09-12 NEW USE FOR THE TREATMENT OF DIFFICULT CLOSTRIDIUM INFECTIONS

Publications (1)

Publication Number Publication Date
PL3681470T3 true PL3681470T3 (pl) 2024-04-02

Family

ID=60991413

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18773856.2T PL3681470T3 (pl) 2017-09-12 2018-09-12 Lactobacillus casei lub lactobacillus paracasei do stosowania w leczeniu infekcji clostridium difficile

Country Status (15)

Country Link
US (1) US11338002B2 (pl)
EP (1) EP3681470B1 (pl)
JP (2) JP7387587B2 (pl)
KR (1) KR102713227B1 (pl)
CN (1) CN111246839B (pl)
AU (1) AU2018333114B2 (pl)
BR (1) BR112020004780A2 (pl)
CA (1) CA3075235A1 (pl)
DK (1) DK3681470T3 (pl)
ES (1) ES2969690T3 (pl)
IT (1) IT201700101704A1 (pl)
MX (1) MX2020002727A (pl)
PL (1) PL3681470T3 (pl)
RU (1) RU2020112241A (pl)
WO (1) WO2019053604A1 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin
ITUA20164188A1 (it) 2016-06-08 2017-12-08 Sofar Spa Nuovo uso medico di probiotici
IT201600122724A1 (it) 2016-12-02 2018-06-02 Sofar Spa Exopolysaccharides and uses thereof
IT201600127498A1 (it) 2016-12-16 2018-06-16 Sofar Spa Probiotici per uso nella diverticolosi e malattia diverticolare
US20210405023A1 (en) * 2018-10-06 2021-12-30 The Cleveland Clinic Foundation Method for diagnosing clostridioides difficile infection
SG11202103058PA (en) * 2018-10-10 2021-04-29 Nutri Co Ltd Preventive and/or therapeutic agent for clostridium difficile infection
CN114025778B (zh) * 2019-06-05 2024-04-12 Lac2生物群系有限公司 包含细菌菌株副干酪乳杆菌和透明质酸的组合物及其治疗皮肤的用途
IT201900016865A1 (it) * 2019-09-20 2021-03-20 Sofar Spa Composizioni a base di ceppi batterici e loro uso come antinfiammatori
WO2021081362A1 (en) * 2019-10-25 2021-04-29 Newgen 27, Llc Synbiotic compositions for gut microbiota
JP7362417B2 (ja) * 2019-10-25 2023-10-17 ライオン株式会社 口腔内病原性細菌の生育抑制剤、口腔用組成物及び促進剤
US11751597B2 (en) 2019-11-05 2023-09-12 Alfasigma S.P.A. Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
CN112322553B (zh) * 2020-11-30 2022-09-27 四川大学华西医院 一种抗艰难梭菌的乳酸乳球菌及其应用
CN112625983B (zh) * 2021-03-05 2021-05-28 山东中科嘉亿生物工程有限公司 一种对腹泻有治疗效果的干酪乳杆菌L.Casei21及其应用
WO2023287025A1 (ko) * 2021-07-12 2023-01-19 한국생명공학연구원 큐티박테리움 아비덤 균주, 그의 유래의 배양액 및 그의 항균 용도
KR102701916B1 (ko) * 2021-07-12 2024-09-04 한국생명공학연구원 큐티박테리움 아비덤 균주, 그의 유래의 배양액 및 그의 항균 용도
KR102391832B1 (ko) * 2021-08-04 2022-04-28 한국식품연구원 클로스트리디오이데스 디피실 억제용 유산균 복합 균주 및 이를 포함하는 장염증 예방, 치료 또는 개선용 조성물
KR102452957B1 (ko) * 2022-03-14 2022-10-11 한동대학교 산학협력단 프로바이오틱스 균주를 유효성분으로 포함하는 클로스트리디오이데스 디피실레 감염을 예방 또는 치료하기 위한 조성물
KR102539776B1 (ko) * 2022-11-14 2023-06-07 주식회사 바이오뱅크힐링 홀데마넬라 바이포미스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102539773B1 (ko) * 2022-11-14 2023-06-07 주식회사 바이오뱅크힐링 루미노코커스 락타리스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102539772B1 (ko) * 2022-11-14 2023-06-07 주식회사 바이오뱅크힐링 락토코커스 락티스 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN116004483B (zh) * 2023-03-09 2023-06-02 四川厌氧生物科技有限责任公司 一种预防或治疗腹泻的格氏乳球菌及其应用
KR102620187B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 리길락토바실러스 루미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
WO2025033636A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
WO2025033635A1 (ko) * 2023-08-08 2025-02-13 주식회사 바이오뱅크힐링 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
KR102620185B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 블라우티아 호미니스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도
KR102628941B1 (ko) * 2023-08-08 2024-01-26 주식회사 바이오뱅크힐링 프레보텔라 코프리 균주, 및 그의 유래의 소포체 및그의 항염증 및 항균 용도
KR102620188B1 (ko) * 2023-08-08 2024-01-04 주식회사 바이오뱅크힐링 락티카제이바실러스 지애 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
CA2470090A1 (fr) * 2004-06-18 2005-12-18 Bio-K Plus International Inc. Bacteries lactiques et leurs usages dans la prevention de diarrhee associee aux antibiotiques
JP5905032B2 (ja) 2011-02-09 2016-04-20 ラヴィヴォ・アーベー 腸管内微生物叢の回復および再構成のためのシンバイオティクス組成物
ITMI20131467A1 (it) 2013-09-06 2015-03-07 Sofar Spa Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico
ITMI20131473A1 (it) * 2013-09-06 2015-03-07 Sofar Spa Metodo per valutare gli effetti di una composizione comprendente microrganismi sul microbiota intestinale
MA39710A (fr) 2014-04-23 2015-10-29 Sofar Spa Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin

Also Published As

Publication number Publication date
CN111246839A (zh) 2020-06-05
DK3681470T3 (da) 2024-02-05
KR102713227B1 (ko) 2024-10-02
CA3075235A1 (en) 2019-03-21
JP2024003162A (ja) 2024-01-11
US20200306323A1 (en) 2020-10-01
RU2020112241A3 (pl) 2021-11-12
ES2969690T3 (es) 2024-05-22
CN111246839B (zh) 2023-11-21
JP7387587B2 (ja) 2023-11-28
BR112020004780A2 (pt) 2020-09-24
AU2018333114A1 (en) 2020-04-09
JP2020533351A (ja) 2020-11-19
AU2018333114B2 (en) 2024-11-07
RU2020112241A (ru) 2021-10-18
EP3681470B1 (en) 2023-11-08
MX2020002727A (es) 2020-10-28
EP3681470A1 (en) 2020-07-22
JP7801294B2 (ja) 2026-01-16
IT201700101704A1 (it) 2019-03-12
WO2019053604A1 (en) 2019-03-21
KR20200065004A (ko) 2020-06-08
US11338002B2 (en) 2022-05-24

Similar Documents

Publication Publication Date Title
PL3681470T3 (pl) Lactobacillus casei lub lactobacillus paracasei do stosowania w leczeniu infekcji clostridium difficile
IL253782B (en) Recombinant probiotic bacteria
PL2937424T3 (pl) Bakteria kwasu mlekowego, kompozycja ją zawierająca i ich zastosowanie
IL257683A (en) Milk fermentation bacteria that inhibit acidification
IL254975A0 (en) Recombinant bacterium Lactococcus lactis and preparations containing it
ZA201900869B (en) Use of probiotics in the treatment and/or prevention of atopic dermatitis
IL257684A (en) A bacterium for milk fermentation that lowers the concentration of acetaldehyde
IL264232A (en) Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections
PL3387156T3 (pl) Lactobacillus casei do leczenia otyłości i powiązanych zaburzeń metabolicznych
SI3442547T1 (sl) Lactobacillus reuteri MM4-1A za uporabo pri zdravljenju ali preprečevanju motenj avtističnega spektra
ZA201804863B (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
GB2548930B (en) Heat-inactivated Lactobacillus rhamnosis GMNL-464 for use in the prevention of halitosis
SMT201900692T1 (it) Composizione per l'uso del trattamento delle infezioni batteriche
IL260181B (en) Preparations and methods for using new strains of Lactobacillus fermentum
PL3454873T3 (pl) Kompozycja probiotyczna i jej zastosowania
HUE045831T2 (hu) Új Lactobacillus plantarum AMT14 törzs és azt tartalmazó készítmény
GB2524474B (en) Composition and use of lactobacillus reuteri GMNL-89 in treating type 2 diabetes
HUE043451T2 (hu) Lactobacillus rhamnosus baktérium például bakteriális vaginosis kezelésére
IL249152A0 (en) Botulinum toxin for use in the treatment of paratonia
PL3322480T3 (pl) Bakterie Lactobacillus w leczeniu zaburzeń czynności serca
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections
PL3526244T3 (pl) Peptydy pochodzące z propeptydu ntsr3 i ich zastosowanie w leczeniu depresji
PL3442348T3 (pl) Lactobacillus rhamnosus do stosowania w wytwarzaniu produktów fermentowanych
HUP1400338A2 (hu) Probiotikus baktériumok alkalmazása külsõ hallójárat gyulladás kezelésére, továbbá azokat tartalmazó készítmény
GB201709731D0 (en) Probiotic compositions and uses thereof